Simultaneous FMRI and NIRS to Estimate Brain Cerebral Metabolism

Multi-Modal fMRI/NIRS for Estimation of CMRO2 for Neuroimaging Studies of Drug Abuse and Psychiatric Illness Problems

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01825096

Enrollment

Registered

2013-04-05

Start date

2012-03-31

Completion date

2015-12-31

Last updated

2017-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

cerebral metabolism, functional magnetic resonance imaging, near infrared spectroscopy

Brief summary

The principal advantages of functional magnetic resonance imaging (fMRI) with blood-oxygenation- level-dependent (BOLD) contrast for studying brain function are: non-invasiveness, ubiquitous availability, relatively high spatiotemporal resolution, and the ability to map function over the entire brain. Thus, BOLD fMRI is the most widely applied technology to study healthy brain function and pathophysiology associated with disease. In studies of drug abuse and psychiatric illness though, normal assumptions mapping BOLD signals to neurometabolism may be violated. Generally, these effects are ignored, resulting in large study-to-study variability. Quantitative fMRI (qfMRI) measures metabolism directly and is more suitable for studies of drug abuse and psychiatric illness. However, qfMRI is too complex for routine use. Cerebral metabolism during brain activation during visual stimulation measured with a new fMRI approach that is simple enough for clinical applications will be compared to CMRO2 activation measured using standard qfMRI.

Detailed description

Healthy subjects will undergo a single imaging session. During the imaging session, fMRI and simultaneous near-infrared spectroscopy measurements will be made during visual stimulation (e.g., viewing a flashing checkerboard). This is a methods development study focused on comparing a new method for estimating CMRO2 associated with brain activation with the standard fMRI approach for estimating CMRO2.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Eligibility

Sex/Gender

MALE

Age

18 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Male * 18 to 40 years old * Physically healthy by self-report

Exclusion criteria

Diagnosis of current drug abuse/dependence, including nicotine, as assessed by DSM-IV criteria * Current diagnosis of Axis I disorder using DSM-IV criteria, or any Axis I disorder within past 5 years * Current daily use of antipsychotic, antidepressant, or other psychoactive prescription drug, as well as daily use of non-prescription drugs * Life threatening or unstable medical illness, or one that can create marked change in mental state * Heavy caffeine use (greater than 300 mg on a regular, daily basis) * History of seizure disorder * Subjects that report any history or current major medical illness (cardiovascular, pulmonary, psychiatric, or neurological disorders) * Subjects who have metal in their body or suffer from claustrophobia cannot participate in this research study. * Additional MR

Design outcomes

Primary

Measure	Time frame	Description
Changes in brain activity associated with visual stimulation	cross-sectional, start and up to 6 minutes	CMRO2 brain activation in visual cortex associated with visual stimulation

Countries

United States

Outcome results